Plasma long non-coding RNA MALAT1 is associated with distant metastasis in patients with epithelial ovarian cancer

被引:70
作者
Chen, Qingjuan [1 ]
Su, Yongyong [1 ]
He, Xiaopeng [1 ]
Zhao, Weian [1 ]
Wu, Caixia [1 ]
Zhang, Weibo [1 ]
Si, Xiaomin [1 ]
Dong, Bingwei [1 ]
Zhao, Lianying [1 ]
Gao, Yufang [1 ]
Yang, Xiaowen [1 ]
Chen, Jianhui [1 ]
Lu, Jian [1 ]
Qiao, Ximin [1 ]
Zhang, Yuchen [1 ]
机构
[1] Xianyang Cent Hosp, Dept Med Oncol, 78 Renmin East Rd, Xianyang 712000, Shaanxi, Peoples R China
关键词
long non-coding RNA; MALAT1; epithelial ovarian cancer; distant metastasis; POOR-PROGNOSIS; UP-REGULATION; LUNG-CANCER; PROMOTES; STATISTICS; EXPRESSION; BIOMARKER; LNCRNAS; OVEREXPRESSION; PROLIFERATION;
D O I
10.3892/ol.2016.4800
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
Human metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) is a newly identified metastasis-associated long non-coding RNA. In a previous study, it was identified that plasma levels of MALAT1 were significantly increased in gastric cancer patients with metastasis compared with gastric cancer patients without metastasis and healthy control individuals. However, it is unclear whether plasma levels of MALAT1 may act as a biomarker for evaluating the development of metastasis in epithelial ovarian cancer (EOC). In the present study, groups that consisted of 47 patients with EOC and metastasis (EOC/DM), 47 patients with EOC without metastasis (EOC/NDM), and 47 healthy control (HC) individuals were established. Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) was used to detect the level of plasma MALAT1 in these groups. The results showed that levels of plasma MALAT1 were significantly increased in the EOC/DM group compared with the EOC/NDM and HC groups (P<0.001). Receiver operating characteristic (ROC) analysis indicated that plasma MALAT1 yielded an area under the curve (AUC) of 0.820 [95% confidence interval (CI), 0.734-0.905; P<0.001], distinguishing between EOC/DM and EOC/NDM. ROC analysis also yielded an AUC of 0.884 (95% CI, 0.820-0.949; P<0.001), with 89.4% sensitivity and 72.3% specificity for distinguishing between EOC/DM and HC. Furthermore, multivariate analysis indicated that overexpression of MALAT1, differentiation (poor), tumor-node-metastasis stage (IV), lymph node metastasis (N3), peritoneal invasion (present) and higher serum carbohydrate antigen 125 levels were independent predictors of survival (hazard ratio, 3.322; P=0.028) in patients with EOC. Kaplan-Meier analysis revealed that patients with increased MALAT1 expression had a poorer disease-free survival time. In conclusion, the levels of plasma MALAT1 may act as a valuable biomarker for the diagnosis of metastasis.
引用
收藏
页码:1361 / 1366
页数:6
相关论文
共 43 条
[1]
[Anonymous], 2010, AJCC CANC STAGING MA
[2]
[Anonymous], 2015, NCCN clinical practice guidelines in oncology: Prostate cancer
[3]
[Anonymous], CANC MED
[4]
Arita T, 2013, ANTICANCER RES, V33, P3185
[5]
Barakat Richard R., 2009, Principles and Practice of Gynecologic Oncology
[6]
Cao BP, 2016, DISCOV MED, V21, P159
[7]
Patterns and progress in ovarian cancer over 14 years [J].
Chan, John K. ;
Cheung, Michael K. ;
Husain, Amreen ;
Teng, Nelson N. ;
West, Dee ;
Whittemore, Alice S. ;
Berek, Jonathan S. ;
Osann, Kathryn .
OBSTETRICS AND GYNECOLOGY, 2006, 108 (03) :521-528
[8]
Plasma miR-122 and miR-192 as potential novel biomarkers for the early detection of distant metastasis of gastric cancer [J].
Chen, Qingjuan ;
Ge, Xiaojun ;
Zhang, Yuchen ;
Xia, Hongwei ;
Yuan, Dandan ;
Tang, Qiulin ;
Chen, Liang ;
Pang, Xiaohui ;
Leng, Weibing ;
Bi, Feng .
ONCOLOGY REPORTS, 2014, 31 (04) :1863-1870
[9]
MALAT1 promotes the proliferation and metastasis of osteosarcoma cells by activating the PI3K/Akt pathway [J].
Dong, Yongqiang ;
Liang, Guojun ;
Yuan, Bo ;
Yang, Chaoqun ;
Gao, Rui ;
Zhou, Xuhui .
TUMOR BIOLOGY, 2015, 36 (03) :1477-1486
[10]
Personalizing CA125 Levels for Ovarian Cancer Screening [J].
Dorigo, Oliver ;
Berek, Jonathan S. .
CANCER PREVENTION RESEARCH, 2011, 4 (09) :1356-1359